USANA Health Sciences (NYSE:USNA) Rating Increased to Buy at Wall Street Zen

USANA Health Sciences (NYSE:USNA) was upgraded by investment analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

Several other equities research analysts have also recently commented on USNA. Weiss Ratings reissued a “sell (d)” rating on shares of USANA Health Sciences in a report on Monday, December 29th. Zacks Research raised USANA Health Sciences from a “strong sell” rating to a “hold” rating in a research note on Monday, February 16th. Two analysts have rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, USANA Health Sciences currently has a consensus rating of “Reduce” and an average target price of $36.00.

USANA Health Sciences Stock Performance

Shares of USNA stock opened at $21.69 on Friday. The firm has a market capitalization of $396.46 million, a PE ratio of 39.43, a price-to-earnings-growth ratio of 0.81 and a beta of 0.67. USANA Health Sciences has a 1 year low of $18.48 and a 1 year high of $38.32. The stock has a fifty day moving average of $20.71 and a two-hundred day moving average of $23.53.

USANA Health Sciences (NYSE:USNA) last posted its quarterly earnings data on Tuesday, February 17th. The company reported $0.60 earnings per share for the quarter, topping the consensus estimate of $0.41 by $0.19. The business had revenue of $226.20 million during the quarter, compared to the consensus estimate of $225.96 million. USANA Health Sciences had a net margin of 1.16% and a return on equity of 6.75%. Equities research analysts predict that USANA Health Sciences will post 2.45 earnings per share for the current fiscal year.

Institutional Trading of USANA Health Sciences

Several institutional investors and hedge funds have recently bought and sold shares of USNA. Nantahala Capital Management LLC purchased a new stake in USANA Health Sciences during the fourth quarter valued at about $11,485,000. Millennium Management LLC boosted its stake in USANA Health Sciences by 715.7% in the 4th quarter. Millennium Management LLC now owns 285,416 shares of the company’s stock worth $5,603,000 after purchasing an additional 250,424 shares during the period. Two Sigma Investments LP raised its stake in USANA Health Sciences by 349.8% during the 3rd quarter. Two Sigma Investments LP now owns 160,933 shares of the company’s stock valued at $4,434,000 after purchasing an additional 125,158 shares during the period. UBS Group AG lifted its holdings in shares of USANA Health Sciences by 252.3% in the fourth quarter. UBS Group AG now owns 138,334 shares of the company’s stock valued at $2,715,000 after purchasing an additional 99,063 shares in the last quarter. Finally, Tudor Investment Corp ET AL boosted its position in shares of USANA Health Sciences by 354.8% in the fourth quarter. Tudor Investment Corp ET AL now owns 109,686 shares of the company’s stock worth $2,153,000 after buying an additional 85,570 shares during the period. Institutional investors and hedge funds own 54.25% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc is a Utah‐based company that develops, manufactures and distributes nutritional supplements and personal care products through a network of independent distributors. Founded in 1992 by Dr. Myron Wentz, the company’s portfolio includes vitamins, minerals, dietary supplements, weight‐management products and skin‐care formulations. USANA’s products are formulated in its own laboratories to meet pharmaceutical‐grade standards, and the company has invested heavily in research and development and quality control to support its offerings.

Operating primarily through a direct selling model, USANA serves markets in North America, Asia Pacific, Europe and Latin America.